Stock Ratings / Health Care / CRVS / financials

PHAR (51) IVA (49) ALMS (19) OBX (34) ⌘ Pro Terminal →

Corvus Pharmaceuticals Inc. (CRVS) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$10.03 -1.95% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $9.98

Corvus Pharmaceuticals Inc. (CRVS) carries a Roarable Rating of E (Strong Sell) with 27/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (27/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $860.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CRVS Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CRVS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Corvus Pharmaceuticals Inc. (NASDAQ: CRVS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $10.03 (-1.95% 1D, market cap $860.6M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CRVS ranks #920 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CRVS compare to PHAR and IVA in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CRVS carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PHAR (Pharming Group N.V. ADS each representing 10) holds a D grade (51/100 RQD, P/E N/A, ROIC —, cap $856.7M) and IVA (Inventiva S.A. American Depository Shares) posts a D grade (49/100 RQD, P/E N/A, ROIC —, cap $881.3M). Among the 5-stock peer group, CRVS leads on earnings multiple (N/A) while CRVS leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CRVS?

▼

Per CRVS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001626971), Corvus Pharmaceuticals Inc. generated $0 in revenue, -$15.3M in net income, and -$33.0M in free cash flow against $71.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $9.98 (-0.54%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (27/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-14% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CRVS)Realized 20D OHLCV Swing Band: ±11.9%

Deterministic 5-Pillar Attribution (27/100 Composite)

🔍 WHY CRVS SCORES 27/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (37% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+7/20 pts (26% of score)

FRED Regime × Technicals: 18% of 52W Range • RSI-14 at 42.9 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$10.05-4% Next Q

Q2 (-2Q)

Grade E$9.65+8.3% Next Q

Q3 (-1Q)

Grade E$10.45-4% Next Q

Current

Grade E$10.03-10.3% Hist 90D α

Trajectory: E (35) → E (27)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CRVS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CRVS currently carries a cautious 27/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($11.86) and Max Pain ($10.53) forces dealer call-delta covering toward $28.30.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CRVS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CRVS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 27%NO 73%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How CRVS Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $4.00B

FY24

Rev $4.00B

FY25

Rev $4.00B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.00B	52%	-1.1%	-$15.3M	-$33.0M	-45%
FY 2024	$4.00B	52%	-0.7%	-$62.3M	-$25.4M	-45%
FY 2023	$4.00B	52%	-0.6%	-$27.0M	-$23.9M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CRVS)

✓Walkthrough of CRVS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CRVS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -37.39%▼ DESCENDING CHANNEL

2026-11-02O $10.52H $10.52L $10.03C $10.03VOL 852.7K

RES: $14.38SUP: $8.43SMA50: $11.86SMA200: $14.46

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CRVS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CRVS Butterfly Map → + Track CRVS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CRVS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CRVS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CRVS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CRVS)

Health Care Rank #920 of 1016 ⚔️ PHAR vs CRVS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CRVS vs. PHAR, IVA, ALMS, OBX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Corvus Pharmaceuticals Inc. (CRVS) ranks #920 by composite RQD confidence (27/100, grade E) and #380 by equity capitalization ($860.6M). Within this direct 5-issuer industry benchmark cohort, CRVS leads on earnings valuation at N/A trailing P/E, while CRVS leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. PHAR currently holds the highest overall quantitative score in the immediate peer group at 51/100 (D) compared with CRVS at 27/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CRVS ACTIVE Corvus Pharmaceuticals Inc.	E	27/100	—	—	-35.0%	-1.95%	$860.6M	Benchmark Subject
PHAR Pharming Group N.V. ADS each representing 10	D	51/100	—	—	—	+0.82%	$856.7M	/phar-vs-crvs →
IVA Inventiva S.A. American Depository Shares	D	49/100	—	—	—	-2.14%	$881.3M	/iva-vs-crvs →
ALMS Alumis Inc.	E	19/100	—	—	-35.0%	-2.32%	$891.8M	/alms-vs-crvs →
OBX Obsidian Therapeutics Inc.	E	34/100	—	—	-35.0%	+1.86%	$896.9M	/obx-vs-crvs →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001626971

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Corvus Pharmaceuticals Inc. (CRVS) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$15.3M, operating cash flow of -$32.8M, and free cash flow of -$33.0M (-29.7% YoY). On the balance sheet, CRVS closed FY2025 with $71.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$15.3M	-$32.8M	-$33.0M	$71.1M	—
FY2024 (FY)	2024-12-31	$0	-$62.3M	-$25.4M	-$25.4M	$68.9M	—
FY2023 (FY)	2023-12-31	$0	-$27.0M	-$23.9M	-$23.9M	—	—

3. CRVS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CRVS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does CRVS compare to PHAR and IVA in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for CRVS?

Where is CRVS trading relative to its 50-day, 200-day, and 52-week technical levels?

CRVS last traded at $10.03 (-1.95% on volume of 845,206 shares), positioning the stock -15.43% below its 50-day simple moving average ($11.86) and -30.64% below its 200-day simple moving average ($14.46). Across its 52-week range of $6.39 to $26.95, CRVS sits at the 17.7% percentile with a 14-day RSI of 42.9 (NEUTRAL RANGE) and an implied next-earnings move of ±11.9% ($8.84 to $11.22).

CRVS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Corvus Pharmaceuticals Inc. (CRVS)?

In FY 2025 (10-K), CRVS converted $4.0B of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: CRVS RQD Cockpit CRVS 12M Forecast CRVS Earnings & Move CRVS Dividends & DRIP CRVS Insiders & 13F CRVS Whale Options CRVS Profit Sankey CRVS News & Why

ROARABLE RATING BRIEF • RQD 27/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

CRVS — Corvus Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:32:20Z

Roarable Rating Brief: What This Means to a Prospective Investor

The Roarable RQD rating assigns CRVS a score of 27 out of 100 and a letter grade of E, with a verdict label of "Roarable Strong Sell — Forensic Risk / Avoid" (per the Roarable RQD rating). The five pillars are:

Fundamental Cash Engine: 4 / 20. Per the Roarable RQD rating, this pillar reflects ROIC of -35% and FCF yield of -3.83%. For an investor, this indicates the business is currently consuming capital rather than generating it, which removes the cash-flow support that typically anchors valuation.
Whale 13F Flow: 3 / 20. The pillar covers institutional accumulation and options positioning. The source provides only the score and label, with no underlying 13F detail, so the signal can be read as weak but its composition is not available in source data.
Insider Conviction: 3 / 20. The pillar covers SEC Form 4 and Congressional PTR cluster flow. As with the whale pillar, the source provides the score without the underlying transactions.
Macro Regime Fit: 7 / 20. Per the Roarable RQD rating, beta is 1.0 and the pillar reflects sector sensitivity. A beta of 1.0 means the stock is expected to move in line with the market, so this pillar does not offer a defensive profile.
Forensic Balance Sheet: 10 / 20. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 2/9, and Debt/Equity is 0.5. These are mixed, with the Piotroski result pointing to weak financial quality.

Taken together, the score implies that the upside case rests on events outside the reported cash engine, such as the catalysts listed below, rather than on current fundamentals. A prospective investor would need to weigh the tradeoff between a stock price that has recovered sharply from its 52-week low and a set of pillars that are uniformly weak.

Business

Corvus Pharmaceuticals Inc. (CRVS) is a NASDAQ-listed issuer in the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry (per the profile). The company's products, customers, and revenue model are not described in the source data. Reported revenue is $0.0M in each of the periods provided (per the SEC financials), which indicates no reported revenue in those years.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-43.0M	$-15.3M	N/A	$-33.0M	$4.6M	N/A
FY 2024	$0.0M	$-27.5M	$-62.3M	N/A	$-25.4M	$8.7M	N/A
FY 2023	$0.0M	$-23.4M	$-27.0M	N/A	$-23.9M	N/A	N/A

Per the SEC financials and market data, the company reports zero revenue and negative operating income, with operating, gross, and net margins all at 0% in the market data. ROIC is -35% (per the market data). Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, with Debt/Equity at 0.5. The reported cash balance declined from $8.7M in FY 2024 to $4.6M in FY 2025 (per the SEC financials).

Recent Catalysts & News Wire Analysis

Catalyst (GREEN): A Stocktwits report headlined that CRVS stock surged 10% and hit its 50-day moving average for the first time in a month, citing a Goldman Sachs upside figure. The headline attributes a 166% upside view to Goldman Sachs; the underlying analyst data is not provided in source data.
Market Wire (YELLOW): Corvus announced a business update and third-quarter 2026 financial results to be released on November 5, 2026 (per a Yahoo Finance report, corroborated by a Moomoo report stating an after-market release on November 5).
Market Wire (YELLOW): A Benzinga report references a Q2 2026 earnings call transcript.
Market Wire (YELLOW): A TradingView report lists a Q3'26 EPS estimate of (0.19) USD.
Market Wire (YELLOW): A Kalkine report notes the stock was up 4.46% premarket.

Risk watch: the market data shows the stock down -2.76% on the day, and the 52-week range is wide ($6.39 to $26.95). The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals, so no signal-level catalysts are confirmed beyond the news wire.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be mapped from the source data. The sector is Health Care and the industry is Biotechnology: Pharmaceutical Preparations, but no linkage to peers or suppliers is provided. An investor should treat the absence of mapped links as a gap in the available evidence rather than as evidence of independence.

Open Questions

What are the company's products, pipeline stage, and revenue model, given zero reported revenue in each period?
What drove the net income swing from $-62.3M in FY 2024 to $-15.3M in FY 2025, and what is the composition of other income?
What is the current cash runway, given cash of $4.6M against negative FCF of $-33.0M in FY 2025?
What is the outcome of the Goldman Sachs analysis referenced in the Stocktwits headline, and is any consensus rating available?
What specific 13F, Form 4, and Congressional transactions underlie the whale (3/20) and insider (3/20) pillar scores?

CRVS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Corvus Pharmaceuticals Inc. (CRVS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CRVS Debate Forum (3) ↓

🟢 CATALYST Stocktwits • 5h ago

CRVS Stock Surges 10%, Hits 50-DMA For First Time In A Month – Here’s Why Goldman Sachs Sees A 166% Upside

Stocktwits report covering Corvus Pharmaceuticals Inc. (CRVS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 8h ago

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2026 Financial Results on November 5, 2026

Yahoo Finance report covering Corvus Pharmaceuticals Inc. (CRVS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 11h ago

Corvus Pharma Q2 2026 Earnings Call Transcript - Corvus Pharmaceuticals (NASDAQ:CRVS)

Benzinga report covering Corvus Pharmaceuticals Inc. (CRVS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Moomoo • 14h ago

Corvus Pharmaceuticals (CRVS.US) will release its financial report after market hours on November 5.

Moomoo report covering Corvus Pharmaceuticals Inc. (CRVS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 17h ago

CRVS Q3'26 Earnings: EPS estimate is (0.19) USD

TradingView report covering Corvus Pharmaceuticals Inc. (CRVS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Kalkine • 20h ago

Why Is Corvus Pharmaceuticals (NASDAQ:CRVS) Up 4.46% Premarket?

Kalkine report covering Corvus Pharmaceuticals Inc. (CRVS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Moomoo • 23h ago

Mizuho Securities Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Cuts Target Price to $27

Moomoo report covering Corvus Pharmaceuticals Inc. (CRVS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST https://www.dars.gov.et/ • 1d ago

CRVS Q2 2026 Earnings: Wider-Than-Expected Loss Keeps Pre-Revenue Biotech in Focus - EPS Growth Report

https://www.dars.gov.et/ report covering Corvus Pharmaceuticals Inc. (CRVS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CRVS Bull vs. Bear Conversation Board — What's Your Call at $10.03?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CRVS 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $9.00 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is CRVS (E • RQD 27/100) a Buy at $10.23?

Welcome to the CRVS (Corvus Pharmaceuticals Inc.) Roar Pit. Current RQD Composite is 27/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $7.77 (-24.0%)

Spot @ $10.23

Pump the brakes on CRVS — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on CRVS, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Corvus Pharmaceuticals Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH 🎯 Target: $11.97 (+17.0%)

Spot @ $10.23

CRVS cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on CRVS, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $10.23 (52-wk range $6.39 - $26.95), any beat on forward guidance forces shorts and underweight funds to chase.